Table 2.
Patient characteristics at baseline.
| Study | Raju et al. | Deftereos et al. | LoDoCo | COLIN | LoDoCo-MI | COLCOT | LoDoCo-2 | COPS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colchicine | Placebo | Colchicine | Placebo | Colchicine | Placebo | Colchicine | Placebo | Colchicine | Control | Colchicine | Placebo | Colchicine | Placebo | Colchicine | Nonexposed | |
| Number of patients | 40 | 40 | 100 | 96 | 282 | 250 | 23 | 21 | 119 | 118 | 2366 | 2379 | 2762 | 2760 | 396 | 399 |
| Mean age (y) | 57.2 | 57.2 | 63.7 | 63.5 | 66 | 67 | 60.1 | 59.7 | 61 | 61 | 60.6 | 60.5 | 65.8 | 65.9 | 59.7 | 60.0 |
| Male (%) | 85 | 93 | 63 | 68 | 89 | 89 | 82.5 | 76.2 | 75 | 79 | 80.1 | 81.6 | 83.5 | 85.9 | 81 | 78 |
| Diabetes (%) | 18 | 15 | 100 | 100 | 33 | 28 | 13.0 | 14.3 | 23 | 21 | 19.5 | 20.9 | 17.8 | 18.7 | 19 | 19 |
| Hypertension (%) | 48 | 38 | 48 | 49 | — | — | 39.1 | 47.6 | 54 | 41 | 50.1 | 52 | 51.4 | 50.3 | 51 | 50 |
| Smoker (%) | 45 | 43 | 36 | 40 | 4 | 6 | 73.9 | 66.7 | 65 | 57 | 29.9 | 29.8 | 11.5 | 12.0 | 32 | 37 |
| Medications (%) Aspirin |
100 | 100 | — | — | 931 | 941 | -2 | -2 | 99 | 100 | 98.6 | 98.9 | 66.9 | 67.1 | 99 | 98 |
| Statin | 100 | 95 | — | — | 96 | 94 | — | — | 97 | 100 | 98.9 | 99.1 | 93.9 | 94.0 | 98 | 99 |
| ACEI/ARB | — | — | — | — | 55 | 60 | — | — | 96 | 92 | — | — | 72.2 | 71.2 | 88 | 86 |
| Beta-blocker | — | — | — | — | 62 | 71 | — | — | 93 | 92 | 89.4 | 88.3 | 61.3 | 62.9 | 81 | 85 |
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker. 1Aspirin and/or clopidogrel. 2As per authors, all patients received aspirin at the time of primary PCI, but the percentage of patients that remained on aspirin in each arm is not stated.